UK‑based DNA Electronics presented data advancing its LiDia‑SEQ cartridge sequencing platform as a rapid, automated diagnostic for bloodstream infections and cancer, targeting same‑day results from whole blood. DNAe plans commercialization activities in 2027 aimed at sepsis detection and antimicrobial resistance markers. Ocean Dx reported a clinical evaluation in which its rapid blood‑based infectious assay matched reference cultures with 100% sensitivity and specificity and returned results in five hours, tripling pathogen detection in the study. Both companies highlight a commercial shift toward culture‑free, time‑to‑result diagnostics that could change antibiotic stewardship and sepsis management. Hospitals, antimicrobial stewardship programs, and payers will monitor validation across diverse patient cohorts and the integration of rapid assays into clinical pathways and reimbursement frameworks.